Aethlon Medical (NASDAQ:AEMD) Stock Passes Below 200 Day Moving Average – Time to Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.40 and traded as low as $2.66. Aethlon Medical shares last traded at $2.66, with a volume of 46,450 shares traded.

Analysts Set New Price Targets

AEMD has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Trading Down 7.6%

The stock has a market capitalization of $2.02 million, a price-to-earnings ratio of -0.12 and a beta of 1.64. The stock’s 50 day moving average is $4.30 and its 200 day moving average is $9.40.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). On average, sell-side analysts anticipate that Aethlon Medical, Inc. will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.